Spruce Biosciences Inc at Jefferies London Healthcare Conference Transcript
Great. So welcome, everyone, to the 31st Annual Healthcare Conference at Credit Suisse. I am Tiago Fauth; I am a biotech analyst here at Credit Suisse. We're joined today by Spruce Bio. Javier, CEO, is going to do a quick presentation, with some Q&A towards the end.
Thank you. Thank you, Tiago. My name is Javier Szwarcberg. It's a real pleasure to be here. I am the CEO of Spruce. I'm going to move forward from our forward-looking statements, which I'll be making along my presentation. And I wanted to first tell you what Spruce is. We are an early-stage biotech company, currently developing tildacerfont for the treatment of CAH as well as PCOS. I'll be spending the majority of my time talking to you about CAH. In the latter part of my deck, I'll discuss some pediatrics -- our pediatric efforts and our PCOS effort.
So CAH is a large, fairly large, market opportunity. It's a $3 billion market opportunity with a high unmet medical need, which was
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |